Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
3 stories
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Xencor reported Phase 1 XmAb819 results in kidney cancer and Adlai Nortye set an AN4035 presentation, joining earlier Nanobiotix, NovaBridge and Eikon ESMO updates.
SEC filing (5)
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)